NIKKEI 225
27,806.97 -128.65 (-0.46%) HANG SENG
23,759.49 +100.57 (+0.43%) CRUDE OIL
66.29 +0.72 (+1.10%) GOLD FUTURES
1,782.40 -1.90 (-0.11%) DOW
34,022.04 -461.68 (-1.34%) BTC-GBP
43,032.74 -136.76 (-0.32%)
Tavistock Investments PLC (TAVI.L)
| Previous close | 4.1000 |
| Open | 3.7800 |
| Bid | 3.7000 x 0 |
| Ask | 4.7000 x 0 |
| Day's range | 3.7800 - 3.7800 |
| 52-week range | 1.2800 - 5.9000 |
| Volume | |
| Avg. volume | 728,314 |
| Market cap | 24.92M |
| Beta (5Y monthly) | 0.68 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.0000 |
| Earnings date | 19 Jul 2021 - 23 Jul 2021 |
| Forward dividend & yield | 0.00 (1.09%) |
| Ex-dividend date | 16 Sept 2021 |
| 1y target est | N/A |
- Business Wire
inTEST Names Richard Rogoff Vice President of Corporate Development
MT. LAUREL, N.J., September 29, 2021--inTEST (NYSE American: INTT) Names Richard Rogoff Vice President of Corporate Development
- Globe Newswire
Active Biotech Year-end report January – December 2020
New strategic R&D plan implemented and financed Fourth quarter in briefTasquinimod The clinical study in multiple myeloma was presented at an oral poster session at the virtual American Society of Hematology (ASH) 2020 meeting in DecemberPatent granted in China in October regarding treatment of multiple myeloma Patent granted in Europe in November regarding use of tasquinimod in combination with immunotherapy Laquinimod Development continued according to plan Naptumomab Active Biotech received a milestone payment from NeoTX in December Corporate Board of Directors proposed in November a rights issue to fund ongoing and planned development programsA Capital Markets Day was held on November 24The clinical strategy and projected development milestones presented to the market in November Significant events during the January-December period Active Biotech announced a new strategic direction for the company in FebruaryThree new board members with extensive topic expertise were appointed at the Annual General Meeting on May 19Preclinical data on tasquinimods effects in experimental models for multiple myeloma were presented at the Virtual Edition of the 25th European Hematology Association (EHA) Annual Congress Meeting in JuneData on the effects of laquinimod in experimental uveitis published in the Journal of Immunology in MayFirst patient dosed in the phase Ib/IIa study of tasquinimod to treat multiple myeloma in AugustA topical ophthalmic formulation of laquinimod to be used to treat inflammatory eye disorders developed in August in collaboration with Leukocare AG Events after the end of the period Rights issue prospectus published on January 5, 2021Rights issue oversubscribed by 175% and added 76.2 MSEK to liquidity before issue expensesActive Biotech signed an agreement for manufacturing of a topical ophthalmic formulation of laquinimod for clinical use Financial summary SEK MOct-DecJan-Dec 2020 201920202019 Net sales6.20.96.78.4Operating profit/loss -4.1-11.2-32.3-32.3Profit/loss after tax-4.1-11.2-32.2-34,1Earnings per share (SEK)-0,03-0,08-0,22-0.24Cash and cash equivalents (at close of period) 26.259.7 For further information, please contact: Helén Tuvesson, CEO Tel: +46 (0)46 19 21 56 Hans Kolam, CFO Tel: +46 (0)46 19 20 44 Active Biotech AB(Corp. Reg. No. 556223-9227)Box 724, SE-220 07 LundTel: +46 (0)46 19 20 00 The report is also available at www.activebiotech.com. Active Biotech is obligated to make public the information contained in this interim report pursuant to the EU Market Abuse Regulation and the Securities Markets Act. This information was provided to the media, through the agency of the contact person set out above, for publication on February 11, 2021, at 8:30 a.m. CET. Attachment Year-End Report 2020
